Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.

The Journal of urology·2026
Same author

Clinical outcomes of benign prostatic hyperplasia surgery in men with detrusor underactivity versus normal contractility: a systematic review and meta-analysis.

International urology and nephrology·2026
Same author

Improved prostate diffusion imaging using deep learning denoising and phase correction with ultra-high-density coil array.

Radiology advances·2026
Same author

VHU-Net: Variational hadamard U-Net for body MRI bias field correction.

Medical image analysis·2026
Same author

Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment.

PloS one·2025
Same author

Next-Generation Advances in Prostate Cancer Imaging and Artificial Intelligence Applications.

Journal of imaging·2025
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K

Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review.

Jason Koehler1, Simon Han2, Samuel Tremblay3

  • 1College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.

Cancers
|April 26, 2025
PubMed
Summary
This summary is machine-generated.

Focal therapy (FT) for prostate cancer (PCa) requires specific follow-up. Surveillance should combine PSA testing, mpMRI, and biopsies, with specific PSA rise thresholds indicating potential recurrence.

Keywords:
failurefocal therapyprostate cancersurveillance

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.3K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.6K

Related Experiment Videos

Last Updated: May 9, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.3K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.6K

Area of Science:

  • Urology
  • Oncology
  • Medical Imaging

Background:

  • Focal Therapy (FT) is an emerging treatment for prostate cancer (PCa).
  • Limited research exists on post-FT patient surveillance due to its novelty.
  • Current guidelines lack established roles for non-PSA biomarkers and PSMA PET in follow-up.

Purpose of the Study:

  • To review current literature on surveillance strategies after FT for PCa.
  • To summarize recommendations for biomarkers, imaging, and biopsies in post-FT follow-up.
  • To highlight the need for standardized surveillance protocols.

Main Methods:

  • Literature review of current research on FT surveillance.
  • Analysis of biomarkers, imaging techniques, and biopsy protocols.
  • Examination of consensus statements and scoring systems for post-FT evaluation.

Main Results:

  • Routine surveillance should include PSA testing, multiparametric MRI (mpMRI), and biopsies.
  • Suspicion for recurrence is raised by PSA increases of 1.0 ng/mL (12 months) or 1.5 ng/mL (24-36 months) over nadir.
  • Standardized scoring systems like PI-FAB or TARGET improve mpMRI interpretation consistency after FT.

Conclusions:

  • A combination of PSA, mpMRI, and biopsies is recommended for FT surveillance.
  • Specific PSA kinetics and standardized imaging interpretation are crucial for detecting recurrence.
  • Further research is needed to refine surveillance protocols and establish roles for novel biomarkers.